FINWIRES · TerminalLIVE
FINWIRES

Kelun Biotech to Present Study Results of Cancer Drugs at American Oncology Meeting

By

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) will present the results of its registrational studies on sacituzumab tirumotecan (sac-TMT) and lunbotinib fumarate at the 2026 American Society of Clinical Oncology annual meeting, according to a filing by parent Sichuan Kelun Pharmaceutical (SHE:002422) with the Shenzhen bourse.

Its study on its sacituzumab tirumotecan drug versus pembrolizumab for advanced non-small cell lung cancer treatment showed a higher response rate for its sac-TMT against pembrolizumab, the filing said.

The company will also present results from its study on lunbotinib, which showed an objective response rate of 87.1% on patients with RET-fusion positive non-small cell lung cancer in patients with prior chemotherapy.

Related Articles

Asia

Market Chatter: Indonesia to Offer Flexibility for US Exports Under Earning Retention Policy

Indonesia is easing rules requiring natural resource explorers to retain a portion of their earnings in state-owned banks for mining exports to the US, among other countries, The Jakarta Globe reported Thursday, citing a senior official.Under a new policy, the state is requiring businesses to place 100% earnings into state-owned banks for at least a year, except firms in the oil sector, which need to park 30% for a minimum of three months.However, companies exporting to nations with trade agreements or a mutual understanding with Indonesia will see some flexibility, the report said, citing Chief Economic Affairs Minister Airlangga Hartarto.They will be required to put 30% of the proceeds for at least three months in state or certain non-state banks fitting specific criteria, the report quoted Airlangga as saying.Airlangga identified the U.S. as a trade partner eligible for the exemptions without naming any others. The two nations had signed a tariff deal in February, according to the report.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^JKSE
Asia

Fuan Pharmaceutical Subsidiary Gets China Approval for Three Injectable Drugs

China's drug regulator granted Fuan Pharmaceutical (SHE:300194) subsidiary Fu'an Pharmaceutical Group Qingyutang Pharmaceutical approval for three injectables, according to a Friday disclosure to the Shenzhen bourse.Mivacurium chloride injection is used together with anesthesia to help relax skeletal musicles, while polidocanol is used for varicose veins and cefoxitin sodium is indicated for severe lower respiratory tract infections, urinary tract infections, and intra-abdominal infections.

$SHE:300194
Asia

Haidilao International's CEO Boosts Shareholding

Haidilao International's (HKG:6862) Chair, CEO, and Controlling Shareholder Zhang Yong acquired nearly 11.4 million ordinary shares in the firm, according to a Friday filing with the Hong Kong bourse.The shares were purchased from the open market on Thursday and Friday for an average price of approximately HK$13.39 apiece.Zhang now, directly and indirectly, holds 2.09 billion shares in the hotpot operator, representing 37.56% of its total issued shares.

$HKG:6862